UNSPSC 51152003: Rocuronium

This classification denotes a nicotinic antagonist with the molecular formula C32H53N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WRE554RFEZ. European Medicines Agency schedules rocuronium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04260MIG. ROCURONIUM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, ROCURONIUM remains the US FDA Preferred Term for this commodity.

Rocuronium bears US NLM identifiers UMLS ID C0209337 and NCI Concept Code C80999. SMILES: O(C1C2(C(C3C(C4(C(CC3)CC(O)C(N3CCOCC3)C4)C)CC2)CC1[N]1(CCCC1)CC=C)C)C(=O)C.

UNSPSC 51152003 Rocuronium is a Commodity code that nominally covers a specific paralytic agent used in anesthesia and critical care; however, the recent state and local opportunities tagged under this code show a substantial mismatch with the code's core scope. The Seminole County, Florida procurement solicits naloxone (an opioid antagonist) and drug deactivation systems—products unrelated to rocuronium—through an IFB, while the Texas Health and Human Services Commission RFI explores direct-to-manufacturer prescription fulfillment models without specifying particular pharmaceutical products. Neither opportunity aligns with procurement of rocuronium itself. The code shows little relevant recent activity for rocuronium specifically; state and local buyers appear to be using this code tag inconsistently or the indexed opportunities reflect broader pharmaceutical and drug-safety procurement mislabeled at the commodity level.

Geographically, the indexed activity spans Florida and Texas, but these records do not establish a pattern of rocuronium procurement. The Seminole County IFB (IFB60459723LAS), due July 26, 2023, targets 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to Sanford, Florida. The Texas HHS Commission RFI (HHS0017013), posted April 3, 2026, with a response deadline of April 3, 2026, seeks vendor capability information on direct pharmaceutical contracting but does not name rocuronium or anesthesia agents as part of its inquiry. Bidders pursuing this code should verify whether rocuronium is actually being solicited by target jurisdictions, as the current indexed records suggest the code is either tagged incorrectly or state and local procurement offices are using it as a catch-all for pharmaceutical acquisitions outside the agent's actual market segment.